KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Precigen (PGEN) Research & Development (2016 - 2025)

Precigen (PGEN) has disclosed Research & Development for 14 consecutive years, with $12.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 8.86% to $12.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.1 million, a 15.11% decrease, with the full-year FY2024 number at $53.1 million, up 9.17% from a year prior.
  • Research & Development was $12.4 million for Q3 2025 at Precigen, up from $11.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $15.7 million in Q2 2024 to a low of $10.5 million in Q1 2025.
  • A 5-year average of $12.1 million and a median of $11.9 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 190.54% in 2021, then decreased 26.8% in 2025.
  • Precigen's Research & Development stood at $10.8 million in 2021, then decreased by 0.17% to $10.8 million in 2022, then grew by 20.39% to $13.0 million in 2023, then dropped by 9.51% to $11.8 million in 2024, then increased by 5.26% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for PGEN's Research & Development are $12.4 million (Q3 2025), $11.5 million (Q2 2025), and $10.5 million (Q1 2025).